MAP2K1 and cancer: The effect of MEK1 inhibition has also been shown in the context of esophageal and gastric adenocarcinomas with the MEK1 inhibitor selumetinib, effectively reducing the migratory properties of cancer cells and metastasis formation in MACC1+ xenografted mouse models [15].